Fresenius Medical Care (NYSE:FMS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Friday. The firm set a “strong-buy” rating on the stock.

A number of other research firms have also recently issued reports on FMS. Truist Financial boosted their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Stock Down 2.2 %

Shares of Fresenius Medical Care stock opened at $22.15 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care has a 52-week low of $17.93 and a 52-week high of $24.31. The company’s 50 day moving average price is $22.21 and its 200-day moving average price is $20.64. The stock has a market capitalization of $13.00 billion, a price-to-earnings ratio of 18.31, a P/E/G ratio of 0.96 and a beta of 0.93.

Hedge Funds Weigh In On Fresenius Medical Care

Institutional investors have recently bought and sold shares of the stock. Creative Planning lifted its position in Fresenius Medical Care by 18.9% during the second quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after buying an additional 6,373 shares during the period. Verition Fund Management LLC purchased a new position in Fresenius Medical Care during the 3rd quarter valued at about $237,000. Wulff Hansen & CO. boosted its stake in Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Fresenius Medical Care by 11.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after purchasing an additional 2,233 shares during the period. Finally, Quantinno Capital Management LP grew its holdings in Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares during the period. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.